Pediatric antifungal therapy. Part I: Focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients

U. D. Allen, E. Bow, J. Doyle, S. Richardson, J. Robinson, C. Rotstein, D. Davies, C. Hui, N. Le Saux, M. Laverdiere, S. Read

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The number of available antifungal agents has significantly increased in recent years. These agents are starting to take over niches that were previously occupied by conventional amphotericin B. For many of these agents, pediatric data from randomized trials are generally lacking and clinicians are faced with extrapolating from data generated in adult patients. This notwithstanding, this report summarizes recommendations that define the roles of newer antifungal agents in the treatment of selected scenarios among immunocompromised pediatric patients. The report includes the outcome of a Canadian conference on the use of antifungal agents in children, supplemented by literature reviews and incorporating information from existing national or international guidelines, where appropriate. The focus of the report is on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and selected aspects of the management of invasive candidiasis.

Original languageEnglish (US)
Pages (from-to)57-69
Number of pages13
JournalMinerva Pediatrica
Volume62
Issue number1
StatePublished - Feb 1 2010

Fingerprint

Invasive Candidiasis
Febrile Neutropenia
Aspergillosis
Antifungal Agents
Immunocompromised Host
Pediatrics
Amphotericin B
Therapeutics
Guidelines

Keywords

  • Antifungal agents
  • Child
  • Mycoses

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pediatric antifungal therapy. Part I : Focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients. / Allen, U. D.; Bow, E.; Doyle, J.; Richardson, S.; Robinson, J.; Rotstein, C.; Davies, D.; Hui, C.; Le Saux, N.; Laverdiere, M.; Read, S.

In: Minerva Pediatrica, Vol. 62, No. 1, 01.02.2010, p. 57-69.

Research output: Contribution to journalReview article

Allen, UD, Bow, E, Doyle, J, Richardson, S, Robinson, J, Rotstein, C, Davies, D, Hui, C, Le Saux, N, Laverdiere, M & Read, S 2010, 'Pediatric antifungal therapy. Part I: Focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients', Minerva Pediatrica, vol. 62, no. 1, pp. 57-69.
Allen, U. D. ; Bow, E. ; Doyle, J. ; Richardson, S. ; Robinson, J. ; Rotstein, C. ; Davies, D. ; Hui, C. ; Le Saux, N. ; Laverdiere, M. ; Read, S. / Pediatric antifungal therapy. Part I : Focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients. In: Minerva Pediatrica. 2010 ; Vol. 62, No. 1. pp. 57-69.
@article{708fa53ccb5a45daa99bc64fa08f0b52,
title = "Pediatric antifungal therapy. Part I: Focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients",
abstract = "The number of available antifungal agents has significantly increased in recent years. These agents are starting to take over niches that were previously occupied by conventional amphotericin B. For many of these agents, pediatric data from randomized trials are generally lacking and clinicians are faced with extrapolating from data generated in adult patients. This notwithstanding, this report summarizes recommendations that define the roles of newer antifungal agents in the treatment of selected scenarios among immunocompromised pediatric patients. The report includes the outcome of a Canadian conference on the use of antifungal agents in children, supplemented by literature reviews and incorporating information from existing national or international guidelines, where appropriate. The focus of the report is on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and selected aspects of the management of invasive candidiasis.",
keywords = "Antifungal agents, Child, Mycoses",
author = "Allen, {U. D.} and E. Bow and J. Doyle and S. Richardson and J. Robinson and C. Rotstein and D. Davies and C. Hui and {Le Saux}, N. and M. Laverdiere and S. Read",
year = "2010",
month = "2",
day = "1",
language = "English (US)",
volume = "62",
pages = "57--69",
journal = "Minerva Pediatrica",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Pediatric antifungal therapy. Part I

T2 - Focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients

AU - Allen, U. D.

AU - Bow, E.

AU - Doyle, J.

AU - Richardson, S.

AU - Robinson, J.

AU - Rotstein, C.

AU - Davies, D.

AU - Hui, C.

AU - Le Saux, N.

AU - Laverdiere, M.

AU - Read, S.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - The number of available antifungal agents has significantly increased in recent years. These agents are starting to take over niches that were previously occupied by conventional amphotericin B. For many of these agents, pediatric data from randomized trials are generally lacking and clinicians are faced with extrapolating from data generated in adult patients. This notwithstanding, this report summarizes recommendations that define the roles of newer antifungal agents in the treatment of selected scenarios among immunocompromised pediatric patients. The report includes the outcome of a Canadian conference on the use of antifungal agents in children, supplemented by literature reviews and incorporating information from existing national or international guidelines, where appropriate. The focus of the report is on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and selected aspects of the management of invasive candidiasis.

AB - The number of available antifungal agents has significantly increased in recent years. These agents are starting to take over niches that were previously occupied by conventional amphotericin B. For many of these agents, pediatric data from randomized trials are generally lacking and clinicians are faced with extrapolating from data generated in adult patients. This notwithstanding, this report summarizes recommendations that define the roles of newer antifungal agents in the treatment of selected scenarios among immunocompromised pediatric patients. The report includes the outcome of a Canadian conference on the use of antifungal agents in children, supplemented by literature reviews and incorporating information from existing national or international guidelines, where appropriate. The focus of the report is on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and selected aspects of the management of invasive candidiasis.

KW - Antifungal agents

KW - Child

KW - Mycoses

UR - http://www.scopus.com/inward/record.url?scp=77952766237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952766237&partnerID=8YFLogxK

M3 - Review article

C2 - 20212399

AN - SCOPUS:77952766237

VL - 62

SP - 57

EP - 69

JO - Minerva Pediatrica

JF - Minerva Pediatrica

SN - 0026-4946

IS - 1

ER -